Long-term persistence with mirabegron in a real-world clinical setting

Area of Science:

• Urology
• Pharmacology

Background:

• Overactive bladder (OAB) affects millions globally, impacting quality of life.
• Mirabegron is a beta-3 adrenergic agonist used for OAB treatment.
• Long-term persistence data in real-world settings are crucial for treatment evaluation.

Purpose of the Study:

• To evaluate the long-term persistence rate of mirabegron in a real-world clinical setting.
• To identify factors influencing mirabegron discontinuation in patients with overactive bladder.

Main Methods:

• Retrospective analysis of 556 patients prescribed mirabegron.
• Investigation of persistence rates and reasons for discontinuation.
• Inclusion of patient demographics, diagnosis, OAB Symptom Score, and treatment history.

Main Results:

• Overall, 401 patients had overactive bladder; 155 had other storage symptoms.
• 170 (42%) OAB patients discontinued mirabegron due to unmet expectations, adverse events, or symptom improvement.
• Persistence rates were similar across age, OABSS, and specialist prescription; older males showed higher persistence.
• 3-year persistence rates for OAB patients were 46% (female) and 51% (male).
• Add-on therapy with antimuscarinics showed higher persistence in female OAB patients compared to drug-naïve patients.

Conclusions:

• Mirabegron demonstrates a relatively good long-term persistence rate in overactive bladder patients.
• Combined therapy with antimuscarinics may enhance mirabegron persistence.
• Real-world data support mirabegron's utility in managing OAB symptoms.